Thromboembolism in Patients Receiving Progestational Drugs

Abstract

ORALLY active derivatives of progesterone and 19-norsteroids are of use in prevention of conception and in the treatment of several gynecologic disorders. These drugs have been in clinical use for more than six years and are being taken by nearly 1,000,000 women.¹ Very few side effects arising from the use of these agents have been reported in the American medical literature. The British Family Planning Association has recently described 5 women in whom thromboembolic phenomena developed while they were receiving norethynodrel and ethynylestradiol-3-methyl ether (Enovid), hereafter referred to as norethynodrel. Four of these women had had prior phlebothrombosis during pregnancy. . . .